Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis

Circulation

Volumn 100, Issue 11, 1999, Pages 1223-1229

  Tummala, Pradyumna E ^a   Chen, Xi Lin ^a   Sundell, Cynthia L ^b   Laursen, Jørn Bech ^c   Hammes, C Patricia ^b   Alexander, R Wayne ^a   Harrison, David G ^a   Medford, Russell M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AtheroGenics Inc   (United States)

^c University of Copenhagen   (Denmark)

Author keywords

Angiotensin; Hypertension; NF B; VCAM 1

Indexed keywords

ANGIOTENSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; PROTEASOME INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; GENE EXPRESSION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

EID: 0033554453     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.11.1223     Document Type: Article

References (43)

1. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995; 25:155-161.
2. Lithell H. Pathogenesis and prevalence of atherosclerosis in hypertensive patients. Am J Hypertens. 1994;(7 pt 2):2S-6S.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature. 1993;362:801-809.
4. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi RG, Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 1989;59:1203-1211.
5. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577-584.
6. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251: 788-791.
7. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis [see comments]. J Clin Invest. 1993; 92:945-951.
8. Li H, Cybulsky MI, Gimbrone MAJPL. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 1993;143:1551-1559.
9. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. VCAM-1 gene transcription and expression is regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
10. Weber C, Erl W, Pietsch A, Strobel M, Ziegler-Heitbrock H, Weber P. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kB mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb. 1994; 14:1665-1673.
11. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
12. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-609.
13. Alderman MH. Plasma renin activity and coronary heart disease: are they related. Curr Opin Nephrol Hypertens. 1995;4:201-203.
14. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J. 1994;128:1328-1332.
15. Yusuf S, Pepine CJ, Garces C, Pouieur H, Salem S, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions Lancet. 1992;240:1173-1178.
16. Griendling K, Minieri C, Ollerenshaw J, Alexander R. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
17. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
18. Laursen JB, Boesgaard S, Poulsen HE, Aldershvile J. Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo. Cardiovasc Res 1996; 31:814-819.
19. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:2479-2488.
20. Chen XL, Tummala PE, Olliff L, Medford RM. E-selectin gene expression in vascular smooth muscle cells: evidence for a tissue specific represser protein. Circ Res. 1997;80:305-311.
21. Ahmad M, Marui N, Alexander RW, Medford RM. Cell type-specific transactivation of the VCAM-1 promoter through an NF-kappa B enhancer motif. J Biol Chem. 1995;270:8976-8983.
22. Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW. Signalinduced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA. 1995;92:11259-11263.
23. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773-785.
24. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. Embo J. 1994;13: 5433-5441.
25. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem. 1992;267:16323-16329.
26. Baeuerle P, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol. 1994;12:141-179.
27. Peng M, Huang L, Xie ZJ, Huang WH, Askari A. Oxidant-induced activations of nuclear factor-kappa B and activator protein-1 in cardiac myocytes. Cell Mol Biol Res. 1995;41:189-197.
28. Krebs LT, Kramar EA, Hanesworth JM, Sardinia MF, Ball AE, Wright JW, Harding JW. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pept. 1996;67:123-130.
29. Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, Loebe M, Gaehtgens P, Fleck E. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 1997;81:804-811.
30. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Comm. 1996;226: 862-868.
31. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasma activtor inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
32. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
33. Taubman MB, Berk BC, Izuma S, Tsuda T, Alexander RW. Angiotensin II induced c-fos mRNA in aortic smooth muscle. J Biol Chem. 1989;264: 526-530.
34. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9: 899-909.
35. Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcriptional factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10:252-264.
36. Cambien F, Poirer O, Lecerf L, Evens A, Cambou JP. Arveiler D, Luc G, Bard JM, Bara L, Richard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
37. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
38. Chobanian AV, Haudenschild CC. Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;12:327-331.
39. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65-S72.
40. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation. 1996;93:333-339.
41. Capers Q, Alexander RW, Lou P, Leon HD, Wilcox JN, Ishizaka N, Howard AB, Taylor RW. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997;30:1397-1402.
42. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension. 1995;25:132-138.
43. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 1991;18: 132-141.